SU11274

Ligand id: 5057

Name: SU11274

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 114.2
Molecular weight 567.17
XLogP 3.74
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

References
1. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. (2011)
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.
Nat. Biotechnol., 29 (11): 1039-45. [PMID:22037377]
2. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ. (2013)
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Biochem. J., 451 (2): 313-28. [PMID:23398362]
3. Haddad R, Lipson KE, Webb CP. (2001)
Hepatocyte growth factor expression in human cancer and therapy with specific inhibitors.
Anticancer Res., 21 (6B): 4243-52. [PMID:11908677]
4. Longati P, Comoglio PM, Bardelli A. (2001)
Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene.
Curr Drug Targets, 2 (1): 41-55. [PMID:11465538]
5. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. (2002)
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.
Cytokine Growth Factor Rev., 13 (1): 41-59. [PMID:11750879]
6. Wang X, Le P, Liang C, Chan J, Kiewlich D, Miller T, Harris D, Sun L, Rice A, Vasile S et al.. (2003)
Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion.
Mol. Cancer Ther., 2 (11): 1085-92. [PMID:14617781]